Table 2.

Anti-trichomonal activities of subfractions D_1–9.

Subfractions / Drug	24 hrs		48 hrs
	LC50 (µg/ml)	LC90 (µg/ml)	LC50 (µg/ml)	LC90 (µg/ml)
C1	35.08±2.89†	238.50± 9.17†	32.69± 4.66†	106.90± 5.21†
D1	34.91 ± 3.14†	246.76±14.86†	49.11± 1.98†	218.26±13.16*,†
D2	61.99± 2.11*,†	300.82± 16.88†	39.90± 1.77†	130.90±10.69†
D3	37.83± 1.54†	188.24± 12.36*,†	34.68±3.05*,†	131.35±10.89†
D4	26.76± 0.99†	204.09±13.25†	56.23± 2.32†	235.11±7.60*,†
D5	33.34± 1.46†	149.20±17.74*,†	44.82± 3.09†	181.85± 7.36†
D6	25.95± 0.78†	112.01±11.56*,†	46.56±4.26†	135.10± 5.33†
D7	13.81± 1.27*	41.26± 8.10*,†	12.38±4.34*	37.71± 2.79*,†
D8	30.40± 3.30†	127.47± 8.77*,†	22.03± 0.30*	72.21± 2.97*
D9	55.24±0.30*,†	318.27±19.95*,†	31.97±1.95†	118.22±4.99†
Metronidazole	13.67± 0.90*	42.86± 0.87*	14.04± 5.85*	61.37±8.69*

D_1–9: VLC subfractions of an active VLC fraction C₁. N = 9; p < 0.05; *: LC₅₀ and LC₉₀ vs C₁; ^†: LC₅₀ and LC₉₀ vs metronidazole. LC₅₀ and LC₉₀: Values ± SEM.